stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Return on assets
Indivior Pharmaceuticals Inc.'s return on assets over the twelve months to 30 September 2026 was 32.8%, up 16.1 percentage points from fiscal 2025 (16.7%). Over the past ten years it has ranged from −9.30% (fiscal 2020) to 27.1% (fiscal 2015); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 16.7% | 16.23 |
| FY2024 | 0.46% | 7.77 |
| FY2023 | −7.31% | (4.37) |
| FY2022 | −2.94% | (15.13) |
| FY2021 | 12.2% | 21.49 |
| FY2020 | −9.30% | (17.68) |
| FY2019 | 8.38% | (10.01) |
| FY2018 | 18.4% | 14.02 |
| FY2017 | 4.37% | 1.11 |
| FY2016 | 3.26% | (23.82) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LQDA Liquidia Corporation compare | 35.6% |
| SUPN Indivior Pharmaceuticals Inc. | 32.8% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 12.9% |
| LNTH Lantheus Holdings, Inc. compare | 11.4% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.44% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 3.01% |
| ALKS Alkermes plc compare | −0.01% |
| HIMS Hims & Hers Health, Inc. compare | −5.16% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −66.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement